Company news

Medexus Pharmaceuticals Inc. news in 2025

Medexus Pharmaceuticals Inc.'s news releases, calls and decks from 2025, newest first.

View company

Medexus Announces Normal Course Issuer Bid, or NCIB, for Its Common Shares

November 20, 2025

Medexus Announces US$51.0 million in New Credit Facilities and Intention to Commence Normal Course Issuer Bid, or NCIB, for its Common Shares

November 17, 2025

Medexus Announces Fiscal Q2 2026 Results, Driven by Strong Year-To-Date Product-Level Performance of GRAFAPEX (treosulfan) for Injection

November 12, 2025

Medexus Schedules Second Fiscal Quarter 2026 Conference Call

November 4, 2025

Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors

September 25, 2025

Medexus Announces Fiscal Q1 2026 Results, Including Positive Results from US Launch of GRAFAPEX (treosulfan) for Injection

August 12, 2025

Medexus Schedules First Fiscal Quarter 2026 Conference Call

August 5, 2025

GRAFAPEX (treosulfan) for Injection Receives CMS Approval of New Technology Add-On Payment (NTAP) for Eligible Cases in CMS's Fiscal Year 2026

August 5, 2025

Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for Injection in the United States

June 25, 2025

Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2025 Conference Call

June 17, 2025

Medexus Successfully Completes Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in Quebec, Canada

April 17, 2025

Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection

April 7, 2025

Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.

March 14, 2025

Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection

February 24, 2025

Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States

February 5, 2025

Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada

February 4, 2025

Medexus Schedules Third Fiscal Quarter 2025 Conference Call

January 31, 2025

Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares

January 31, 2025

Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update

January 22, 2025

Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada

January 15, 2025

Calls in 2025